Pharmacoepidemiology and Drug Safety

Papers
(The H4-Index of Pharmacoepidemiology and Drug Safety is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
94
Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second‐Line Treatment of Advanced Non–Small Cell Lung Cancer75
Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research62
Issue Information52
Quantitative Benefit–Risk Assessment of Vaccination Against COVID‐19: A Systematic Review50
Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries46
Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data44
Data Resource Profile: The Danish National Hospital Medicine Register43
Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster‐Level Confounding: A Parametric and Plasmode Simulation Study Based on US 41
Correction to “Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using 35
Mixed Impact of Direct Healthcare Professional Communications When Considering Proximal Outcomes and the Targeted Population: A Systematic Review33
External validity in distributed data networks33
Development and Validation of an Endometrial Cancer Algorithm in US Claims Data31
Warfarin‐Associated Bleeding and Thromboembolic Events in Sub‐Saharan Africa: A Systematic Review and Meta‐Analysis28
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark27
Issue Information27
ORAL PRESENTATION26
All Lines Is the Right Approach: Selecting Patient Lines of Therapy for an External Comparator Arm25
Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study23
Optimizing therapeutic decision‐making for off‐label medicines use: A scoping review and consensus recommendations for improving practice and research+22
Letter to the Editor22
Methodological Characteristics in Economic Evaluations of Health Technology Assessment Reports Submitted for Drug Reimbursement in Brazilian Public Health21
Beta Blocker Use and Total Knee Arthroplasty Among United States Medicare Beneficiaries21
0.21498680114746